Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATXN2 | Q99700 | 5/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663877 | 1.00 | ATXN2 (0.43) | ATXN2MAPK8MAPK9GRM4MAPK1 | |
| SCHEMBL17112470 | 0.93 | ATXN2 (0.39) | ATXN2MAPK8MAPK9GRM4MAPK1 | |
| SCHEMBL17112481 | 0.84 | ATXN2 (0.58) | ATXN2MAPK8MAPK9GRM4MAPK1 | |
| SCHEMBL17112472 | 0.83 | ATXN2 (0.39) | ATXN2MAPK8MAPK9GRM4TYK2 | |
| SCHEMBL412178 | 0.82 | KMT2A (0.50) | KMT2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7362112 | 0.80 | PDE4D (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1505645 | 0.80 | ABL1 (0.43) | ATXN2GRM4GABRA5PDE4D | |
| SCHEMBL31705706 | 0.78 | ACACB (0.46) | ATXN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL31704643 | 0.78 | ACACB (0.46) | ATXN2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL412004 | 0.78 | CNR1 (0.52) | ATXN2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216457-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10654857-B2 | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2020-05-19 | — | — | US | disclosed |
| EP-3122750-B1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-20190144457-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20180111941-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-9802944-B2 | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2017-10-31 | — | — | US | disclosed |
| EP-3122750-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20170008900-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2015144605-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654857-B2 | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | ENPP2, LPAR1, LPAR2 | ATXN2 41/4885MAPK8 3125/4885MAPK9 2645/4885 |
| US-20170008900-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | ATXN2 41/4885MAPK8 3125/4885MAPK9 2645/4885 |
| US-20200216457-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | ATXN2 41/4885MAPK8 3125/4885MAPK9 2645/4885 |
| US-20180111941-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | ATXN2 41/4885MAPK8 3125/4885MAPK9 2645/4885 |
| US-20190144457-A1 | BICYCLIC COMPOUNDS AS AUTOTAXIN (ATX) AND LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION INHIBITORS | ENPP2, LPAR1, LPAR2 | ATXN2 41/4885MAPK8 3125/4885MAPK9 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.